Navigation Links
Sunesis Pharmaceuticals Presents Updated Clinical Data From Ongoing Phase 2 Trial of Voreloxin (Formerly SNS-595) in Ovarian Cancer Patients at the 44th ASCO Annual Meeting
Date:5/31/2008

xin at 60 mg/m(2). We are optimistic that the 75 mg/m(2) cohort of this Phase 2 trial will be fully enrolled by year-end, and we look forward to reporting additional efficacy and safety data later this year."

Data from Sunesis' ongoing Phase 2 clinical trial of voreloxin in ovarian cancer were presented today during the Gynecologic Cancer: Ovarian Cancer session in a poster titled "A Phase 2 Trial of Voreloxin (formerly SNS-595) in Women with Platinum-Resistant Epithelial Ovarian Cancer" (Abstract #5582). A copy of the poster will be available on the Sunesis corporate website at http://www.sunesis.com.

About Voreloxin (formerly SNS-595)

Sunesis' lead compound, voreloxin (formerly SNS-595), is a novel naphthyridine analog, structurally related to quinolones, a class of compounds which has not been used previously for the treatment of cancer. Voreloxin both intercalates DNA and inhibits topoisomerase II, resulting in replication-dependent, site-selective DNA damage, irreversible G2 arrest and rapid apoptosis. In addition to the ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer, voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly acute myeloid leukemia (AML) patients, and in a Phase 1b clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML. In clinical trials conducted to date, voreloxin has been generally well tolerated and has shown objective responses in both solid and hematologic tumor types.

About Sunesis Pharmaceuticals

Sunesis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. Sunesis has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therape
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Sunesis Pharmaceuticals to Present Interim Clinical Data From Voreloxin (Formerly SNS-595) Ovarian Cancer Trial at 44th ASCO Annual Meeting and Acute Myeloid Leukemia Trials at 13th EHA Congress
2. Sunesis Pharmaceuticals Initiates Phase 2 Clinical Trial of Voreloxin (SNS-595) in Acute Myeloid Leukemia
3. Sunesis Pharmaceuticals Reports Data from Nonclinical Studies of SNS-032 at the Annual Meeting of the American Association for Cancer Research
4. Sunesis Pharmaceuticals to Present Non-Clinical Data at the Annual Meeting of the American Association for Cancer Research
5. Sunesis Pharmaceuticals Reports Positive Interim Data for SNS-595 Single-Agent Activity in Platinum-Resistant Ovarian Cancer
6. Sunesis Pharmaceuticals to Present Data on Two Product Candidates at the 49th Annual Meeting of the American Society of Hematology
7. Sunesis Pharmaceuticals Reports Preliminary SNS-595 Activity in Ovarian Cancer Clinical Trial at AACR-NCI-EORTC International Conference
8. Sunesis Pharmaceuticals Commences Clinical Trials of SNS-595 and SNS-314
9. Vion Pharmaceuticals to Present Clinical Data on Cloretazine(R) (VNP40101M) at the ASCO(R) Annual Meeting
10. Strativa Pharmaceuticals Announces Preliminary Results from ONCONASE(R) Phase IIIb Clinical Trial
11. Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac(TM) Development at Prestigious International Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/25/2014)... , Oct. 24, 2014 Burzynski Research ... and Drug Administration (FDA) has given the company permission ... AS2-1 in patients > 3 months of age with ... be placed in one of five treatment groups based ... received prior treatment for DIPG. The primary study endpoint ...
(Date:10/25/2014)... N.C. , Oct. 24, 2014  As ... can provide a company access to diverse skill ... markets, and round-the clock business hours for efficiency. ... difficult hurdles. According to recent ... disappointments, such as seeing a project not move ...
(Date:10/22/2014)...  Cephasonics, a technology-innovation leader with a game-changing embedded-ultrasound ... Ultrasound Box™-1), the first product in a new family ... Cephasonics for purchase by companies to rebrand with their ... showcasing the cQUB-1 for the first time at CMEF ... Chongqing, China from October 23 to 26. ...
Breaking Medicine Technology:Burzynski Research Institute, Inc. Announces FDA Permission to Launch a New Clinical Trial in Diffuse Intrinsic Brainstem Glioma 2Work Around the Clock: Successfully Building & Managing Global Virtual Teams 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3
... April 27, 2011 ACCESS PHARMACEUTICALS, ... leveraging its proprietary drug-delivery platforms to develop treatments in areas ... Nursing Society (ONS) Congress at the Boston Convention and Exhibition ... (#652) will be displayed in the Exhibition Hall of the ...
... PharmaTech (Cayman) Inc. (NYSE: WX ) today ... 20-F for the year ended December 31, 2010 with ... be accessed on WuXi PharmaTech,s website at http://www.wuxiapptec.com ... provide a hard copy of its annual report on ...
Cached Medicine Technology:Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress 2Access Pharmaceuticals to Attend the 36th Annual Oncology Nursing Society Congress 3
(Date:10/25/2014)... QueenBeeTickets.com has a variety of tickets for ... prices. Bob Seger & The Silver Bullet Band tickets ... are going on sale October 25 and are expected ... browse the selection of tickets for Bob Seger & ... singer is touring North America beginning next month, and ...
(Date:10/25/2014)... Mesothelioma researchers are reporting extended survival in a ... his combination drug therapy became too toxic. Click ... on the Surviving Mesothelioma website. , A new ... suggests that “maintenance therapy” with pemetrexed may be the ... higher doses of cisplatin. , “Although the standard ...
(Date:10/25/2014)... HealthDay Reporter FRIDAY, Oct. 24, ... sores -- herpes simplex -- might increase the risk of ... fact, being a carrier of certain antibodies to the virus ... "The identification of a treatable cause [herpes simplex] ... lead researcher Dr. Hugo Lovheim, an associate professor in the ...
(Date:10/25/2014)... (HealthDay News) -- A large influx of international aid ... avoid tens of thousands of deaths from the widening ... Using a specially designed mathematical model, the ... in just one densely populated county of hard-hit Liberia ... Monrovia. The researchers said that if international aid ...
(Date:10/25/2014)... shorter, darker days can trigger a type of depression, ... People affected by seasonal affective disorder, also ... even have trouble getting out of bed. In extreme ... Halaris, a professor in the department of psychiatry and ... Medicine. "Seasonal affective disorder should not be taken ...
Breaking Medicine News(10 mins):Health News:QueenBeeTickets.com Features Bob Seger & The Silver Bullet Band Tickets for Charleston Civic Center, Huntington Center, and Nationwide Arena at Reduced Prices 2Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2
... Steve Pasierb, President , , ... (MTF) indicates the continuation of a promising trend of declining usage ... crack -- among our country,s teens. However, it also indicates several ... Progress , The long-term ...
... and Uplifting TV Movie Portrayal of Tourette Syndrome , ... Nearly 12 million people watched last Sunday night,s Hallmark Hall ... movie based on the true story of a young man,s ... an award winning teacher. The national Tourette Syndrome Association, ...
... - Scientists in the clinic and the laboratory continue ... with breakthrough drugs. With tamoxifen,s discovery 30 years behind ... researchers are studying zoledronic acid, aromatase inhibitors and monoclonal ... presented at the CTRC-AACR San Antonio Breast Cancer Symposium. ...
... Sister Carol Keehan, DC, president and chief executive officer ... issued the following statement: , , ... nomination today of former Senate Majority Leader Tom Daschle to ... person to oversee a new White House Office of Health ...
... The following is a statement by Matthew L. Myers, ... (Logo: http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO ) , ... health that the 2008 Monitoring the Future survey released today ... have declined to the lowest levels recorded in this survey ...
... DNA, study says , , THURSDAY, Dec. 11 (HealthDay ... of DNA damage from prolonged exposure to cosmic ionizing ... pilots to 50 university faculty members from the same ... analyzed for DNA abnormalities, specifically the number of times ...
Cached Medicine News:Health News:Partnership for a Drug-Free America(R) Responds to 2008 Monitoring the Future Study Results 2Health News:Partnership for a Drug-Free America(R) Responds to 2008 Monitoring the Future Study Results 3Health News:Hallmark Hall of Fame Collaboration with Patient Organization Equals Extraordinary Success 2Health News:Cancer drugs in the pipeline 2Health News:Catholic Health Association Statement on the Naming of Tom Daschle and Jeanne Lambrew to Health Leadership Positions in President-Elect Obama's Administration 2Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 2Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 3Health News:New Survey Shows Continued Progress in Reducing Youth Smoking; Congress, States Can Accelerate Declines by Implementing Proven Solutions 4Health News:Pilots May Face Greater Cancer Risk 2
... high-quality light guide cables work in conjunction ... optimal brightness during a number of procedures. ... you the flexibility and ease-of-use necessary to ... fully-autoclavable so they can be easily cleaned ...
... line of affordable, high-quality light guide cables ... sources to provide optimal brightness during a ... durable design give you the flexibility and ... And each is fully-autoclavable so they can ...
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
ACMI™ offers an assortment of fiberoptic light guides, high transmission autoclavable fiberoptic light guides, and light guide adapters to connect our scopes to other manufacturers' light sourc...
Medicine Products: